Clinical Trial Update: Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resistant Depression (TRD) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating MIJ821 for treatment-resistant depression has completed with results posted, assessing efficacy, safety, tolerability, and pharmacokine…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder Treatment-resistant

Drugs mentioned

• MIJ821

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Treatment-Resistant Depression | Phase 2 | Status: COMPLETED | Results posted: 2025-04-04